000			04909nam a22005777a 4500
008			240807s20242024 xxu||||| |||| 00| 0 eng d
022			_a2574-3805
024			_a2820087 [pii]
024			_aPMC11184459 [pmc]
040			_aOvid MEDLINE(R)
099			_a38884994
245			_aEpidemiologic Features of Recovery From SARS-CoV-2 Infection.
251			_aJAMA Network Open. 7(6):e2417440, 2024 Jun 03.
252			_aJAMA netw. open. 7(6):e2417440, 2024 Jun 03.
253			_aJAMA network open
260			_c2024
260			_fFY2024
260			_p2024 Jun 03
265			_sepublish
265			_tMEDLINE
266			_d2024-08-07
266			_z2024/06/17 11:34
520			_aConclusions and Relevance: In this cohort study, more than 1 in 5 adults did not recover within 3 months of SARS-CoV-2 infection. Recovery within 3 months was less likely in women and those with preexisting cardiovascular disease and more likely in those with COVID-19 vaccination or infection during the Omicron variant wave.
520			_aDesign, Setting, and Participants: For this prospective cohort study, standardized ascertainment of SARS-CoV-2 infection was conducted starting in April 1, 2020, across 14 ongoing National Institutes of Health-funded cohorts that have enrolled and followed participants since 1971. This report includes data collected through February 28, 2023, on adults aged 18 years or older with self-reported SARS-CoV-2 infection.
520			_aExposure: Preinfection health conditions and lifestyle factors assessed before and during the pandemic via prepandemic examinations and pandemic-era questionnaires.
520			_aImportance: Persistent symptoms and disability following SARS-CoV-2 infection, known as post-COVID-19 condition or "long COVID," are frequently reported and pose a substantial personal and societal burden.
520			_aMain Outcomes and Measures: Probability of nonrecovery by 90 days and restricted mean recovery times were estimated using Kaplan-Meier curves, and Cox proportional hazards regression was performed to assess multivariable-adjusted associations with recovery by 90 days.
520			_aObjective: To determine time to recovery following SARS-CoV-2 infection and identify factors associated with recovery by 90 days.
520			_aResults: Of 4708 participants with self-reported SARS-CoV-2 infection (mean [SD] age, 61.3 [13.8] years; 2952 women [62.7%]), an estimated 22.5% (95% CI, 21.2%-23.7%) did not recover by 90 days post infection. Median (IQR) time to recovery was 20 (8-75) days. By 90 days post infection, there were significant differences in restricted mean recovery time according to sociodemographic, clinical, and lifestyle characteristics, particularly by acute infection severity (outpatient vs critical hospitalization, 32.9 days [95% CI, 31.9-33.9 days] vs 57.6 days [95% CI, 51.9-63.3 days]; log-rank P < .001). Recovery by 90 days post infection was associated with vaccination prior to infection (hazard ratio [HR], 1.30; 95% CI, 1.11-1.51) and infection during the sixth (Omicron variant) vs first wave (HR, 1.25; 95% CI, 1.06-1.49). These associations were mediated by reduced severity of acute infection (33.4% and 17.6%, respectively). Recovery was unfavorably associated with female sex (HR, 0.85; 95% CI, 0.79-0.92) and prepandemic clinical cardiovascular disease (HR, 0.84; 95% CI, 0.71-0.99). No significant multivariable-adjusted associations were observed for age, educational attainment, smoking history, obesity, diabetes, chronic kidney disease, asthma, chronic obstructive pulmonary disease, or elevated depressive symptoms. Results were similar for reinfections.
546			_aEnglish
650			_a*COVID-19
650			_a*SARS-CoV-2
650			_aAdult
650			_aAged
650			_aCOVID-19/ep [Epidemiology]
650			_aFemale
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aPandemics
650			_aPost-Acute COVID-19 Syndrome
650			_aProspective Studies
650			_aUnited States/ep [Epidemiology]
650			_zAutomated
651			_aMedStar Health Research Institute
657			_aJournal Article
700			_aUmans, Jason G _bMHRI
790			_aOelsner EC, Sun Y, Balte PP, Allen NB, Andrews H, Carson A, Cole SA, Coresh J, Couper D, Cushman M, Daviglus M, Demmer RT, Elkind MSV, Gallo LC, Gutierrez JD, Howard VJ, Isasi CR, Judd SE, Kanaya AM, Kandula NR, Kaplan RC, Kinney GL, Kucharska-Newton AM, Lackland DT, Lee JS, Make BJ, Min YI, Murabito JM, Norwood AF, Ortega VE, Pettee Gabriel K, Psaty BM, Regan EA, Sotres-Alvarez D, Schwartz D, Shikany JM, Thyagarajan B, Tracy RP, Umans JG, Vasan RS, Wenzel SE, Woodruff PG, Xanthakis V, Zhang Y, Post WS
856			_uhttps://dx.doi.org/10.1001/jamanetworkopen.2024.17440 _zhttps://dx.doi.org/10.1001/jamanetworkopen.2024.17440
942			_cART _dArticle
999			_c14534 _d14534